CU20170158A7 - Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales - Google Patents

Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales

Info

Publication number
CU20170158A7
CU20170158A7 CUP2017000158A CU20170158A CU20170158A7 CU 20170158 A7 CU20170158 A7 CU 20170158A7 CU P2017000158 A CUP2017000158 A CU P2017000158A CU 20170158 A CU20170158 A CU 20170158A CU 20170158 A7 CU20170158 A7 CU 20170158A7
Authority
CU
Cuba
Prior art keywords
carboxamidas
arilnaftiridina
cardiovascular
prevention
treatment
Prior art date
Application number
CUP2017000158A
Other languages
English (en)
Inventor
Arapinis Dr Melissa Boultadakis
Dr Markus Brechmann
Dr Daniela Fliegner
Dr Tobias Marquardt
Dr Mark Meininghaus
Thomas Müller
Dr Klaus Münter
Dr Katrin Nowak-Reppel
Anne-Sophie Rebstock
Dr Alexander Straub
Dr Henrik Teller
Mondritzki Thomas
Dr Hanna Tinel
Dr Alexandros Vakalopoulos
Dr Matthias Wittwer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20170158A7 publication Critical patent/CU20170158A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>La presente solicitud se refiere a moduladores alostéricos positivos del receptor M2 muscarínico, especialmente a 1-arilnaftiridina-3-carboxamidas 7 sustituidas novedosas de la fórmula (I)</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>a los procesos de preparación de los mismos, y procesos para producir medicamentos para tratar y/o prevenir enfermedades, en particular para tratar y/o prevenir trastornos cardiovasculares y/o trastornos renales.<br />  </p>
CUP2017000158A 2015-06-09 2016-06-06 Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales CU20170158A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15171127 2015-06-09
EP16156676 2016-02-22
PCT/EP2016/062737 WO2016198342A1 (de) 2015-06-09 2016-06-06 Positiv allosterische modulatoren des muskarinergen m2 rezeptors

Publications (1)

Publication Number Publication Date
CU20170158A7 true CU20170158A7 (es) 2018-06-05

Family

ID=56101466

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000158A CU20170158A7 (es) 2015-06-09 2016-06-06 Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales

Country Status (27)

Country Link
US (2) US10435403B2 (es)
EP (2) EP3307741B1 (es)
JP (1) JP6908536B2 (es)
KR (1) KR20180016485A (es)
CN (1) CN107949562B (es)
AU (1) AU2016274433B2 (es)
BR (1) BR112017026561A2 (es)
CA (1) CA2988468A1 (es)
CL (1) CL2017003124A1 (es)
CO (1) CO2017012622A2 (es)
CR (1) CR20170566A (es)
CU (1) CU20170158A7 (es)
DO (1) DOP2017000288A (es)
EA (1) EA035465B1 (es)
EC (1) ECSP17081322A (es)
HK (1) HK1254348A1 (es)
IL (2) IL256119A (es)
MX (1) MX370113B (es)
NI (1) NI201700154A (es)
PE (1) PE20180252A1 (es)
PH (1) PH12017502224A1 (es)
SG (1) SG11201710164QA (es)
TN (1) TN2017000498A1 (es)
TW (1) TW201716405A (es)
UY (1) UY36714A (es)
WO (1) WO2016198342A1 (es)
ZA (1) ZA201800125B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260025887A (ko) 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
JOP20190045A1 (ar) * 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CN110215899B (zh) * 2019-04-01 2022-03-25 重庆科技学院 一种氨基酸功能化的金属有机骨架材料及其制备方法和应用
BR112021026662A2 (pt) * 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
CN111057045A (zh) * 2019-12-18 2020-04-24 安徽红杉生物医药科技有限公司 Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用
KR20230022829A (ko) * 2020-03-03 2023-02-16 트웬티에잇-세븐, 인크. Rna 결합 단백질 또는 rna 변형 단백질을 표적으로 하는 화합물
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
CN113072480B (zh) * 2021-04-13 2022-09-30 常州佳德医药科技有限公司 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
IT1239283B (it) * 1989-11-08 1993-10-19 Erba Carlo Spa Uso di un agente muscarinico da solo o insieme ad un noto farmaco antiaritmico per la prevenzione e/o il trattamento dell'aritmia ventricolare.
EP0713487B1 (en) 1993-08-13 2000-04-19 Dong Wha Pharmaceutical Industrial Co. Ltd. Novel quinolone carboxylic acid derivatives
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
JP2005511743A (ja) 2001-12-13 2005-04-28 ウォックハート・リミテッド 新世代の三重標的化したキラルな広域スペクトラム抗菌性の７位置換ピペリジノ−キノロンカルボン酸誘導体、その調製方法、組成物、および医薬としての使用
CN1168446C (zh) * 2002-08-26 2004-09-29 夏国瑾 氢溴酸槟榔碱作为制备抗心律失常药物的应用
JP2007505158A (ja) * 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
JP2005012561A (ja) 2003-06-19 2005-01-13 Sony Corp 画像処理装置、画像処理方法および画像投射装置
JP4725047B2 (ja) * 2003-07-24 2011-07-13 アステラス製薬株式会社 キノロン誘導体又はその塩
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
WO2005026165A1 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
DE10343098A1 (de) * 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
CN1914204A (zh) 2003-12-09 2007-02-14 弗特克斯药品有限公司 萘啶衍生物及其作为毒蕈碱性受体调节剂的用途
AU2005245240B2 (en) * 2004-05-20 2010-04-29 Scimar Ltd. Use of drug combinations for treating insulin resistance
TW200800983A (en) * 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
ATE475650T1 (de) * 2005-12-05 2010-08-15 Merck Sharp & Dohme Positive allosterische chinolon-m1- rezeptormodulatoren
CN101411705B (zh) * 2007-10-17 2011-06-01 北京赛德维康医药研究院 用于防治动脉粥样硬化的药物组合物
WO2010093341A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica N.V. C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents
PT2512243E (pt) 2009-12-17 2016-06-08 Merck Sharp & Dohme Moduladores alostéricos positivos de recetor de quinolina amida m1
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
CN103183676B (zh) * 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
SI3215498T1 (sl) 2014-11-03 2018-11-30 Bayer Pharma Aktiengesellschaft Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe
MX375707B (es) 2015-06-09 2025-03-06 Onconic Therapeutics Inc Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.

Also Published As

Publication number Publication date
MX2017016055A (es) 2018-02-21
SG11201710164QA (en) 2018-01-30
BR112017026561A2 (pt) 2018-08-14
PH12017502224A1 (en) 2018-06-04
ZA201800125B (en) 2019-07-31
AU2016274433B2 (en) 2020-07-16
EA035465B1 (ru) 2020-06-22
EP3307741B1 (de) 2020-10-28
EP3692991A1 (de) 2020-08-12
CR20170566A (es) 2018-03-20
CL2017003124A1 (es) 2018-06-01
HK1254348A1 (zh) 2019-07-19
JP2018516970A (ja) 2018-06-28
EP3307741A1 (de) 2018-04-18
EA201890002A1 (ru) 2018-04-30
NI201700154A (es) 2018-10-19
CO2017012622A2 (es) 2018-03-28
ECSP17081322A (es) 2018-01-31
US20180297994A1 (en) 2018-10-18
IL256119A (en) 2018-02-28
CA2988468A1 (en) 2016-12-15
UY36714A (es) 2016-12-30
WO2016198342A1 (de) 2016-12-15
CN107949562B (zh) 2021-07-23
US20190367516A1 (en) 2019-12-05
PE20180252A1 (es) 2018-02-02
TW201716405A (zh) 2017-05-16
IL272017A (en) 2020-02-27
KR20180016485A (ko) 2018-02-14
CN107949562A (zh) 2018-04-20
AU2016274433A1 (en) 2018-01-04
JP6908536B2 (ja) 2021-07-28
MX370113B (es) 2019-12-02
DOP2017000288A (es) 2018-01-31
TN2017000498A1 (en) 2019-04-12
US10435403B2 (en) 2019-10-08

Similar Documents

Publication Publication Date Title
CU20170158A7 (es) Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales
MX385332B (es) Moduladores de ror-gamma.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201790785A1 (ru) Производные тетрагидроизохинолина
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2017014375A (es) Moduladores del ccr2.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
GEAP201814485A (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
EA201790908A1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
UY35746A (es) Derivados de fenilalanina sustituidos
NI201900023A (es) 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1